Provided by Tiger Fintech (Singapore) Pte. Ltd.

ProQR Therapeutics NV

2.01
-0.0300-1.47%
Post-market: 2.00-0.0100-0.50%17:11 EDT
Volume:379.99K
Turnover:769.83K
Market Cap:211.74M
PE:-5.53
High:2.09
Open:2.04
Low:2.00
Close:2.04
Loading ...

BRIEF-ProQR Announces CTA Submission For Phase 1 Study Of AX-0810 Targeting NTCP

Reuters
·
27 Jun

ProQR Seeks EU Approval for Liver Cell Protein Trial

MT Newswires Live
·
27 Jun

ProQR Therapeutics NV Submits Clinical Trial Application for First Human Study of AX-0810 Targeting NTCP, Marking Milestone in Axiomer™ RNA Editing Platform Development

Reuters
·
27 Jun

ProQR Announces Cta Submission for Phase 1 Study of Ax-0810 Targeting Ntcp

THOMSON REUTERS
·
27 Jun

ProQR Therapeutics NV Held Annual General Meeting

Reuters
·
04 Jun

Oppenheimer Adjusts ProQR Therapeutics N.V Price Target to $9 From $15, Maintains Outperform Rating

MT Newswires Live
·
13 May

ProQR Therapeutics NV reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

ProQR Therapeutics Q1 EPS $(0.10) Misses $(0.09) Estimate, Sales $4.75M Beat $4.49M Estimate

Benzinga
·
08 May

ProQR Therapeutics NV expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
02 May

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

GlobeNewswire
·
01 May

ProQR Therapeutics initiated with an Outperform at Evercore ISI

TipRanks
·
30 Apr

ProQR Therapeutics Initiated at Outperform by Evercore ISI Group

Dow Jones
·
29 Apr

Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?

Zacks
·
15 Apr

ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 34%

Simply Wall St.
·
15 Apr

ProQR Appoints Dennis Hom as CFO, Cristina Lopez as CMO

MT Newswires Live
·
14 Apr

ProQR Therapeutics Names Hom as CFO, Lopez Lopez as Chief Medical Officer

Dow Jones
·
14 Apr

ProQR Therapeutics appoints Hom as CFO, Lopez as CMO

TIPRANKS
·
14 Apr

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

GlobeNewswire
·
14 Apr

ProQR Therapeutics Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
14 Mar

BRIEF-Proqr Therapeutics NV Files For Shelf Of Up To Up To 3.5 Million Ordinary Shares By Selling Stockholder - SEC Filing

Reuters
·
13 Mar